Compare STRIDES PHARMA SCIENCE with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs JUBILANT LIFE SCIENCES - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE JUBILANT LIFE SCIENCES STRIDES PHARMA SCIENCE/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 14.5 14.3 101.5% View Chart
P/BV x 0.9 1.7 51.4% View Chart
Dividend Yield % 0.6 0.9 63.5%  

Financials

 STRIDES PHARMA SCIENCE   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
JUBILANT LIFE SCIENCES
Mar-19
STRIDES PHARMA SCIENCE/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,147898 127.7%   
Low Rs642618 104.0%   
Sales per share (Unadj.) Rs317.2572.0 55.5%  
Earnings per share (Unadj.) Rs7.836.2 21.7%  
Cash flow per share (Unadj.) Rs25.159.5 42.1%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.20.6 37.6%  
Book value per share (Unadj.) Rs274.3301.9 90.8%  
Shares outstanding (eoy) m89.50159.28 56.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.81.3 212.8%   
Avg P/E ratio x114.020.9 545.1%  
P/CF ratio (eoy) x35.712.7 280.4%  
Price / Book Value ratio x3.32.5 130.0%  
Dividend payout %25.512.4 205.2%   
Avg Mkt Cap Rs m80,058120,694 66.3%   
No. of employees `0002.52.4 104.9%   
Total wages/salary Rs m4,34119,260 22.5%   
Avg. sales/employee Rs Th11,325.838,120.6 29.7%   
Avg. wages/employee Rs Th1,731.48,058.4 21.5%   
Avg. net profit/employee Rs Th280.12,414.3 11.6%   
INCOME DATA
Net Sales Rs m28,39491,108 31.2%  
Other income Rs m941357 263.2%   
Total revenues Rs m29,33491,466 32.1%   
Gross profit Rs m3,96517,390 22.8%  
Depreciation Rs m1,5403,709 41.5%   
Interest Rs m1,9622,198 89.3%   
Profit before tax Rs m1,40311,840 11.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-2,802 15.6%   
Tax Rs m973,268 3.0%   
Profit after tax Rs m7025,770 12.2%  
Gross profit margin %14.019.1 73.2%  
Effective tax rate %6.927.6 25.1%   
Net profit margin %2.56.3 39.0%  
BALANCE SHEET DATA
Current assets Rs m24,83645,848 54.2%   
Current liabilities Rs m18,99320,897 90.9%   
Net working cap to sales %20.627.4 75.1%  
Current ratio x1.32.2 59.6%  
Inventory Days Days7157 125.0%  
Debtors Days Days11351 222.6%  
Net fixed assets Rs m34,28965,498 52.4%   
Share capital Rs m895159 561.8%   
"Free" reserves Rs m23,65147,930 49.3%   
Net worth Rs m24,54648,089 51.0%   
Long term debt Rs m15,51342,429 36.6%   
Total assets Rs m65,437114,685 57.1%  
Interest coverage x1.76.4 26.9%   
Debt to equity ratio x0.60.9 71.6%  
Sales to assets ratio x0.40.8 54.6%   
Return on assets %4.16.9 58.6%  
Return on equity %2.912.0 23.8%  
Return on capital %6.912.4 55.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69712,422 126.4%   
Fx outflow Rs m73517,227 4.3%   
Net fx Rs m14,962-4,805 -311.4%   
CASH FLOW
From Operations Rs m1,87111,215 16.7%  
From Investments Rs m5,826-10,118 -57.6%  
From Financial Activity Rs m-10,1576,574 -154.5%  
Net Cashflow Rs m-2,6157,612 -34.4%  

Share Holding

Indian Promoters % 27.7 45.6 60.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 37.8 8.7 434.5%  
FIIs % 8.6 21.2 40.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 21.1 122.7%  
Shareholders   56,241 23,815 236.2%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PIRAMAL ENTERPRISES  TTK HEALTHCARE  SUN PHARMA  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 18, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS